Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AT&T Inc. (T) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs AT&T Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while AT&T Inc. trades at $21.21 (market cap $146.82B). The key difference: AT&T Inc. is far larger — about 3.7× Alnylam Pharmaceuticals, Inc.'s market cap, and AT&T Inc. pays a 5.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | T | |
|---|---|---|
Market Cap | $39.89B | $146.82B |
Sector | Health | Media |
52-Week High | $491.22 | $29.62 |
52-Week Low | $278.09 | $20.49 |
Enterprise Value | $38.15B | $292.17B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AT&T (T) trades at $21.13, up 0.48% today but near 52-week lows, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.11, net income margin of 16.94%, and three consecutive quarterly EPS beats. Recent news highlights SpaceX competition concerns, though the company maintains robust cash flow and a 5.3% dividend yield.
The outlook is mixed: valuation appears attractive with analyst consensus target of $26.43 (25% upside), but technical weakness and competitive threats pose risks. Investment opportunity lies in income generation and potential rebound if execution continues, while key risks include debt levels and industry disruption from new entrants.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
